NAFLD Fibrosis Score: Calculation & Meaning
The NAFLD Fibrosis Score is a non-invasive tool used to estimate the degree of liver fibrosis in patients with non-alcoholic fatty liver disease, helping to avoid liver biopsy.
Things worth knowing about "NAFLD Fibrosis Score"
The NAFLD Fibrosis Score is a non-invasive tool used to estimate the degree of liver fibrosis in patients with non-alcoholic fatty liver disease, helping to avoid liver biopsy.
What Is the NAFLD Fibrosis Score?
The NAFLD Fibrosis Score (NFS) is a non-invasive diagnostic tool used to estimate the severity of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). NAFLD refers to the accumulation of excess fat in the liver that is not caused by alcohol consumption. Over time, NAFLD can progress to fibrosis – the abnormal build-up of scar tissue in the liver – which impairs liver function and may lead to serious complications.
The NFS was developed to reduce the need for liver biopsy – an invasive tissue sampling procedure – by providing a reliable estimate of fibrosis stage using simple clinical and laboratory parameters.
How Is the NAFLD Fibrosis Score Calculated?
The NFS is calculated using six readily available clinical and laboratory variables:
- Age (in years)
- Body Mass Index (BMI) (kg/m²)
- Presence of impaired fasting glucose or diabetes mellitus (yes/no)
- AST/ALT ratio (ratio of liver enzymes aspartate aminotransferase to alanine aminotransferase)
- Platelet count (x10&sup9;/L)
- Serum albumin (g/dL)
The formula is:
NFS = –1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m²) + 1.13 × IFG/diabetes (yes=1, no=0) + 0.99 × AST/ALT ratio – 0.013 × platelets (x10&sup9;/L) – 0.66 × albumin (g/dL)
Interpretation of Results
The calculated score is interpreted using established cut-off values:
- NFS < –1.455: Low probability of advanced fibrosis (F0–F2). Advanced fibrosis can be ruled out with high confidence.
- NFS between –1.455 and 0.675: Indeterminate zone – further diagnostic evaluation is recommended.
- NFS > 0.675: High probability of advanced fibrosis (F3–F4). Further workup or liver biopsy is indicated.
Clinical Relevance
The NAFLD Fibrosis Score is a valuable tool in hepatology and primary care settings. It allows clinicians to identify high-risk patients early and make informed decisions about the need for invasive procedures. Regular fibrosis assessment is particularly important in patients with known NAFLD, type 2 diabetes, metabolic syndrome, or obesity.
Advanced liver fibrosis increases the risk of:
- Liver cirrhosis (extensive scarring of liver tissue)
- Hepatocellular carcinoma (liver cancer)
- Liver failure
- Increased mortality from liver disease and cardiovascular events
Advantages and Limitations
Advantages
- Non-invasive and easy to perform
- Based on routinely available laboratory values
- Well-validated across diverse patient populations
- Helps avoid unnecessary liver biopsies
- Cost-effective
Limitations
- May be less accurate in certain groups (e.g., elderly patients or those with diabetes)
- Does not provide a definitive answer in the indeterminate range
- Does not replace histological diagnosis in ambiguous cases
- Does not assess inflammatory activity (NASH activity)
NAFLD Fibrosis Score Compared to Other Scores
Several other non-invasive scoring systems exist for fibrosis assessment in NAFLD, including the FIB-4 index, the APRI score, and imaging-based methods such as liver elastography (FibroScan®). The NFS is considered one of the most thoroughly validated scores for NAFLD-specific fibrosis assessment and is recommended in international clinical guidelines.
References
- Angulo P. et al. - The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007; 45(4): 846–854. (PubMed PMID: 17393509)
- European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) - EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology, 2016; 64(6): 1388–1402.
- Chalasani N. et al. - The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018; 67(1): 328–357.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.